Nachrichten zur Myriad Genetics Aktie

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

…

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the…

Myriad Genetics: Significantly Undervalued With Profitability In Sight

…

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better…

Myriad Genetics Announces Inducement Awards

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular…

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.22%, respectively, for the quarter ended December 2024. Do the…

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday,…

MYGN Stock Might Rise on Collaboration With CancerCARE

Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latters network with access to…

MYGN Stock Gains Following the Launch of Know More Sooner

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive…

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program…

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Strategic progress and solid potential in oncology testing keep MYGN on investors radar.…

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from…

New NCCN Guidelines Boost Myriad Genetics Prolaris: Stock to Gain?

Myriad Genetics Prolaris test reinforced as an Advanced Tool by the NCCN for prognostic assessment.…

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.…

MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.…

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims…

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS…

Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript

…

MYGN Beats on Q3 Earnings and Revenues, Raises 24 EPS View

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.…

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing…

Should You Continue to Retain MYGN Stock in Your Portfolio?

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors sentiment.…

Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%

The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…

Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76%

According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript

…

Myriad Genetics (MYGN) Q2 Earnings Surpass, 24 Outlook Raised

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term…

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease.…

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.…

Global PCOS Diagnostic Market Size To Exceed USD 6.1 Billion By 2033 | CAGR Of 5.18%

The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023 and the Worldwide PCOS Diagnostic Market…

Global Companion Diagnostics Market Size To Exceed USD 23.12 Billion By 2033 | CAGR Of 12.50%

The Global Companion Diagnostics Market Size was Valued at USD 7.12 Billion in 2023 and the Worldwide Companion Diagnostics Market…

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.…

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in…

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime…

GNW-Adhoc: QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik

^Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD)basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungenund…

QIAGEN N.V.: QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik

Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD) basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungen und proprietären, von der FDA zugelassenen ...…

Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript

…

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in…

Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…

Myriad Genetics (MYGN) Announces Favorable Research Results

Myriad Genetics (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.…

Heres Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) strong solvency position and improvement in testing volume.…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

Myriad Genetics (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to…

BioHive to launch HealthTech Hub Chapter to Empower Medical Innovation and Disrupt Healthcare

Salt Lake City, Utah, March 13, 2024 (GLOBE NEWSWIRE) -- BioHive, a nonprofit public-private partnership dedicated to enhancing…

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

Myriad Genetics (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential…

Myriad Genetics target raised to $28 on firm outlook By Investing.com

Myriad Genetics target raised to $28 on firm outlook…

Earnings call: Myriad Genetics reports positive 2023 results, eyes growth By Investing.com

Earnings call: Myriad Genetics reports positive 2023 results, eyes growth…

Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript

…

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.…

Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s…